These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9247561)

  • 1. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
    Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
    Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
    Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
    Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
    Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
    Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
    Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
    J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies.
    Garcia de Palazzo I; Klein-Szanto A; Weiner LM
    Int J Biol Markers; 1993; 8(4):233-9. PubMed ID: 7908024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
    Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
    J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
    Fagerberg J; Frödin JE; Wigzell H; Mellstedt H
    Cancer Immunol Immunother; 1993 Sep; 37(4):264-70. PubMed ID: 8348565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
    Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.
    Keler T; Guyre PM; Vitale LA; Sundarapandiyan K; van De Winkel JG; Deo YM; Graziano RF
    J Immunol; 2000 Dec; 165(12):6738-42. PubMed ID: 11120792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
    Baral R; Sherrat A; Das R; Foon KA; Bhattacharya-Chatterjee M
    Int J Cancer; 2001 Apr; 92(1):88-95. PubMed ID: 11279611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
    J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.